Moreover, combining the anti-PD-1 mAb and anti-CTLA-4 mAb administration enhanced the RT-induced distant antitumor effects involved in the accumulation of HER2-tumor antigen-specific CD8-positive T cells at HER2-positive tumor sites. The gene discussed is CD8A; the disease is neoplasm.